Results 141 to 150 of about 36,022 (296)

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Zachary Bloomgarden
wiley   +1 more source

How lipid ingestion is sensed: the mechanisms underlying intestinal hormone secretion. [PDF]

Clin Sci (Lond)
Santos-Hernández M, Gribble FM, Reimann F.   +2 more
europepmc   +1 more source

The ciliary neurotrophic factor induces Stat3 phosphorylation in distinctive cytotypes of organs involved in body metabolism: An immunohistochemical study

Journal of Anatomy, EarlyView.
p‐STAT3‐positive cells in metabolically relevant peripheral organs and tissues from mice administered with recombinant CNTF (0.3 mg/kg). Abstract Administration of ciliary neurotrophic factor (CNTF) reduces food intake and body weight in both humans and experimental animals, where it also ameliorates hyperglycemia, hyperinsulinemia, and dyslipidemia ...
Chiara Galli, Georgia Colleluori, Jessica Perugini, Edoardo Scopini, Ilenia Severi, Gaia Grandin, Antonio Giordano   +6 more
wiley   +1 more source

Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study. [PDF]

PLoS One
Kazi MAI, Mufarrih SM, Sirohi A, Hasan F, Sharma A, Singh S, Muganlinskaya N, Haq N.   +7 more
europepmc   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey, Irene Pomares‐Bri, Paula de Juan‐Maciá, Mariló Olivares‐Vicente, Enrique Barrajón‐Catalán, Vicente Micol, Enrique Roche, María Herranz‐López   +7 more
wiley   +1 more source

Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis

Obesity Reviews, EarlyView.
ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim, Lima Hamidi, Anne Majumdar, Matyas Fehervari, Emma Rose McGlone   +4 more
wiley   +1 more source

Glycemic and bodyweight effects of <i>GIPR</i> coding variation reflect differences in surface expression and intrinsic functional impairment. [PDF]

Sci Adv
Manchanda Y, Desoki R, Gardner EJ, Perry JRB, Wainscott DB, Stutsman C, Langenberg C, Coghlan M, Bhatnagar P, Ho JD, Yonkunas M, Sloop KW, Ong KK, Wareham NJ, Tomas A, Jones B.   +15 more
europepmc   +1 more source

Cardiovascular Outcomes of GLP‐1–Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta‐Analyses of Randomized Controlled Trials

Obesity Reviews, EarlyView.
ABSTRACT Introduction Cardiovascular (CV) outcomes of Glucagon‐like peptide‐1 (GLP‐1)–based medicines among people with overweight and obese (OW/OB) population have been investigated by meta‐analyses of randomized controlled trials (RCTs), but an overall summary is lacking.
Muhammed Rashid, E. Lyn Lee, Sajesh K. Veettil, Teerapon Dhippayom, Alice Y. Y. Cheng, Juliana Simonetti, Nathorn Chaiyakunapruk   +6 more
wiley   +1 more source

Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists. [PDF]

World J Transplant
Elatrebi S, Abuyadek R, Abdelbar SMM, Ahmad MS, Ayyad M, Quoritem MA, Abdel Majid RO, Arafat M, Amgad A, Alnagar A.   +9 more
europepmc   +1 more source

Incretin‐Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice

Obesity Reviews, EarlyView.
ABSTRACT Introduction Pregnancy concurrent with incretin‐based medications is contraindicated due to unknown risk of teratogenicity, as is breastfeeding. The aim of this systematic scoping review was to investigate potential risks and benefits of incretin‐based medications in relation to preconception, pregnancy, and postnatal health, and to propose ...
Kate Maslin, Jill Shawe, Sinead Blowers, Michael Ceulemans, Kathryn Hart, Sam Schoenmakers, Amihai Rottenstreich, Heather Hopper, Mojca Jensterle, Angela C. Flynn, Sarah Siegelaar, Annick Bogaerts, Isy Douek, Nicola Heslehurst, Dries Ceulemans, Tricia Tan, Johnathan Pinkney, Martin Whyte, Shahrad Taheri, Roland Devlieger   +19 more
wiley   +1 more source